Navigation Links
Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone

fludarabine and rituximab (F-R) in the treatment of patients who have received at least one prior treatment for NHL. The trial is expected to enroll 300 patients.

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplify administration compared to the currently marketed anthracyclines.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of pixantrone to have the same cardiotoxicity profile in humans as demonstrated in preclinical studies or to prove safe and effective for treatment of non-Hodgkin's lymphoma or other cancer, determinations by regulatory, patent and administrative governmental authorities,
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
3. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
4. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
5. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
6. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
7. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
8. Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
11. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
Post Your Comments:
(Date:7/29/2014)... COLORADO SPRINGS, Colo. , July 29, 2014 /PRNewswire-USNewswire/ ... remote-controlled catheter (MARC) which could allow physicians to see ... stroke may hold promise, according to study authors who ... Surgery (SNIS) 11 th Annual Meeting in ... findings stand to advance the field of neurointervention, a ...
(Date:7/29/2014)... and NEW YORK , ... of the executive management team of Caremark Rx, ... Media ( www.pbm365.com ).  PBM365 is the leading independent ... reporting, insight, analysis and opinion on the pharmacy ... will provide insightful and timely coverage of, and context ...
(Date:7/29/2014)... , July 29, 2014  Roche (SIX: RO, ... Association for Clinical Chemistry (AACC) 2014 Clinical Lab Expo ... on the unique ways Roche is partnering with customers ... "Our customers tell us every day that they,re looking ... they deliver in their labs and offices," said ...
Breaking Medicine Technology:New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3Drew Crawford Announces Launch of PBM365 Media 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
... June 15, 2011 The American Academy of ... 2011 AAFP Foundation Pfizer Immunization Award winners. These ... achieved increased immunization rates in their communities through ... the AAFP,s National Conference were presented to 16 ...
... June 15, 2011 To address surgeons, need for ... in open surgery, Ethicon Endo-Surgery, Inc. (EES) today announces ... advanced bipolar technology.  The new technology is designed with ... sealing vessels consistently along the length of the 40mm ...
Cached Medicine Technology:Family Medicine Residency Programs Recognized for Improving Childhood and Adult Immunizations Rates in Underserved Communities 2Family Medicine Residency Programs Recognized for Improving Childhood and Adult Immunizations Rates in Underserved Communities 3Ethicon Endo-Surgery Launches ENSEAL® G2 Super Jaw 2
(Date:7/29/2014)... (PRWEB) July 29, 2014 Biocides are ... and control bacteria or fungi growth and to prevent ... within the material and its surface. It is used ... wood preservation, food and beverage, paints and coatings. It ... and sanitizers, as well as in industrial applications to ...
(Date:7/29/2014)... The U.S. should significantly reform the federal system ... ensure that the public,s $15 billion annual investment ... says a new report by the Institute of ... Medicare -- requires little accountability, allocates funds independent ... insufficient opportunities to train physicians in the health ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Frank Davis, ... powders can help parents add nutrition to their kids’ ... Bites – Key market drivers in kids’ foods market” ... is pleased to announce the interview Frank Davis had ... the Activz organic vegetable and fruit produce powders to ...
(Date:7/29/2014)... State College of Medicine, have jointly received nearly ... data research network., The Patient-Centered Outcomes Research Institute ... and Affordable Care Act, awarded the funds to ... Johns Hopkins University -- and each of their ... together to create a Clinical Data Research Network, ...
(Date:7/29/2014)... July 29, 2014 According to a ... the leading global authority in medical device market research, ... grow to over $8 billion by 2018. This ... in the transcatheter heart valve market, which is comprised ... the transcatheter mitral valve repair (TMVR) segments. , There ...
Breaking Medicine News(10 mins):Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 2Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 3Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 4Health News:$15 billion annual public funding system for doctor training needs overhaul, says IOM 2Health News:$15 billion annual public funding system for doctor training needs overhaul, says IOM 3Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 2Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 3Health News:New network unites university health care research 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 3
... officials have proposed the administration of flu vaccine to all ... attempt to prevent the incidence of seasonal flu. The dreadful ... during winter, had claimed the valuable lives of over 1000 ... Vaccination and Immunisation that addresses important medical issues and provides ...
... women who suffer from stage 1 endometrial cancer along with ... says// that this can prolong their survival. Among the gynecological ... As many as 40,000 women in the US suffer from ... data of the American Cancer Society. ,The ...
... are reforming themselves to come out of the financial ... Patricia Hewitt, British Health secretary as welcomed better financial ... more on cutting unnecessary fund wastage. ... for all the NHS hospitals will be followed and ...
... arrest in supply of blood to the brain cells, which occurs ... caused by a blocked artery and Hemorrhagic stroke is caused due ... sudden stopping of blood to the brain cells can lead to ... stroke, the survival of the stroke patients depend upon the severity ...
... the level of mental sharpness in aging individuals, according ... at Lowell//. , The researchers assessed whether ... aging mice, damage that can lead to memory loss. ... mice using a standard diet, a nutrient-deficient diet, and ...
... 250,000 early-stage glaucoma patients risk blindness due to lack of ... National Institute for the Blind (RNIB).// In an attempt to ... has been launched in the UK. ,Apart from ... from some form of visual impairment in the UK. The ...
Cached Medicine News:
Can download data from your A&D balance directly to your PC saving time and reducing the chances of manually recording the wrong weighing data; 60 month warranty; automatic adjustable environment set...
... The ABI Prism 7000 Sequence Detection ... system that detects and quantitates nulceic ... detection of accumulated PCR product is ... fluorescence detection, and application-specific software in ...
... 3100 system offers continuous, unattended operation ... separation and detection, and data analysis. ... and importing sample information, the operator ... Run command. The instrument requires no ...
Coated-Tube (CT) RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum...
Medicine Products: